Is GLP-1 a Peptide? Yes — and the Distinction People Draw Is Wrong

GLP-1 — glucagon-like peptide-1 — is a peptide hormone. Your intestine releases it after a meal, and it tells the pancreas to release insulin, slows how fast the stomach empties, and signals fullness to the brain. Its active form is a chain of about 30 amino acids.

That puts it squarely inside the definition of a peptide: a short chain of amino acids, conventionally somewhere between 2 and 50, joined by peptide bonds. Longer chains fold into proteins. GLP-1 is nowhere near that length.

The medications are peptides too. The FDA has published specific concerns about unapproved GLP-1 products, and its compounding guidance explains why a compounded version is not the brand product. Semaglutide is a 31-amino-acid analog of human GLP-1, modified so it survives in the bloodstream for days instead of minutes. Tirzepatide is a 39-amino-acid chain engineered to activate two incretin receptors at once.

If a clinic tells you GLP-1s are "not really peptides," that is a marketing statement, not a chemical one.

The word "peptides" got colonised by a specific corner of the market. When a wellness clinic advertises peptide therapy, it usually means a particular set of compounded injectables aimed at recovery, sleep, growth hormone signalling or longevity — the category that grew up largely outside the FDA-approval pathway.

GLP-1 medications took the opposite route. They ran full clinical trials, won FDA approval for type 2 diabetes and later for obesity, and entered the market as pharmaceuticals with brand names and a place in treatment guidelines.

Two different regulatory histories, two different marketing languages, one molecular class. The vocabulary followed the business, not the biochemistry.

What people usually mean when they say "peptides"

In practice, the phrase is doing one of three jobs: naming the chemical class, naming the compounded-injectable product category, or naming a specific mechanism — usually something that prompts your own body to produce more of a hormone. Those are not the same claim, and they are frequently blurred in the same sentence.

The row that actually matters is the third one, and it is the distinction the marketing never makes.

If you want a real dividing line between the things being sold as "GLP-1" and the things being sold as "peptides," it is not chain length. It is whether the molecule does the job itself or asks your body to do it.

Receptor agonists act directly

Semaglutide and tirzepatide are receptor agonists. They bind the same receptors your natural incretin hormones bind and produce the effect themselves. The dose you take is the signal — your own hormone production is not part of the mechanism.

Secretagogues ask your body to act

Sermorelin works the other way. It is a fragment of growth-hormone-releasing hormone — see sermorelin — while our GLP-1 program uses the receptor-agonist route described above. It is a fragment of growth-hormone-releasing hormone, and it prompts the pituitary to release more of your own growth hormone. The ceiling is set by what your body can still produce, and the feedback loops that regulate it stay intact.

That difference has real consequences — for how quickly you notice something, for what happens when you stop, and for who is a reasonable candidate. It is a far more useful thing to ask about than whether a molecule counts as a peptide.

Both, yes.

• Semaglutide — 31 amino acids. A GLP-1 receptor agonist, structurally close to human GLP-1 with modifications that extend its half-life to about a week.
• Tirzepatide — 39 amino acids. A dual agonist that activates both the GIP and GLP-1 receptors, which is why it is not simply "a stronger semaglutide."
• Natural GLP-1 — about 30 amino acids in its active form, and broken down within minutes of release.

Insulin sits right on the boundary at 51 amino acids and is usually called a small protein rather than a peptide — a reminder that the 50-residue cutoff is a convention, not a law of nature.

The category label tells you almost nothing. These are the questions that do:

• Is a licensed physician prescribing it after reviewing labs? Not a questionnaire — actual bloodwork and an actual clinician.
• Is it dispensed by a licensed US compounding pharmacy? Anything sold as a "research chemical" carries no requirement for sterility, purity or accurate dosing.
• Is it an agonist or a secretagogue? That determines what the treatment is actually doing and what happens when it ends.
• What is the follow-up? A molecule without monitoring is a product, not a treatment.

Protocol MD prescribes GLP-1 therapy and peptide therapy from the same clinical process — labs first, physician review, US compounding pharmacy, ongoing follow-up — because from a prescribing standpoint they were never two separate worlds. The assessment is where that starts.